Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

timates include the anticipated contribution of sales of generic Yasmin. On the expense side for 2008, the Company expects R&D investment of approximately $275 - $285 million, and SG&A expenses to be approximately $810 - $830 million.

The Company's adjusted earnings guidance for 2008 excludes the impact of amortization costs associated with acquired products, contributions and/or losses from the DDD&I operations that the Company plans to divest, and incremental depreciation related to purchase accounting. The Company's adjusted earnings guidance also excludes the impact of any unscheduled launches resulting from patent challenges, other business development activities, and refinancing activities that may be completed after the date hereof and on or before December 31, 2008.

Conference Call/Webcast

The Company will host a Conference Call at 8:30 AM Eastern time on Thursday, May 8, 2008 to discuss earnings results for the quarter ended March 31, 2008. The number to call from within the United States is (800) 553-5275 and (612) 332-0345 Internationally. A replay of the conference call will be available from 10:30 AM Eastern time on May 8, 2008 through 11:59 PM Eastern time May 22, 2008 and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using the access code 918406.

The Conference Call will also be Webcast live on the Internet. Investors and other interested parties may access the live webcast through the Investors section, under Calendar of Events, on Barr's website at http://www.barrlabs.com.

Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketi
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
(Date:9/30/2014)... 30, 2014 iLab Solutions announced the ... study which focuses on core facility operations, growth ... managers face today. , In its 4th year running, ... note is the year-over-year decrease in the percentage of ... to be feeling the constraints of this trend. When ...
(Date:9/30/2014)... MA (PRWEB) September 30, 2014 ... (UC) and collaboration company is dedicated to supporting ... connectivity needs. Julie Power, a carrier ... to ensure collaboration solutions stays connected and productive ... to the increased movement of businesses to cloud ...
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
Breaking Biology Technology:OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3SoundConnect Expands Carrier Services Division 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4
... Oct. 26, 2011 The following is a letter ... Ltd. (OTCBB: HADSY), a publicly traded portfolio of biotech ... Hadassah University Hospital. Dear Fellow Investors, ... establishment by the Hadassah University Hospital and its IPO ...
... this smorgasbord of recent salmonella outbreaks in the United ... 2011 alone, and the list goes on, according to ... perhaps not for long, thanks to a promising new ... bacteria before contaminated food or animals reach the marketplace. ...
... and IPSWICH, Mass., Oct. 25, 2011 SwitchGear ... services for studying regulatory elements in the human genome, ... Inc. (NEB) to create a new dual reporter assay ... Luciferase Assay System and NEB,s BioLux® Cypridina ...
Cached Biology Technology:Summary Letter to Hadasit Bio-Holdings Ltd. Shareholders 2Summary Letter to Hadasit Bio-Holdings Ltd. Shareholders 3Summary Letter to Hadasit Bio-Holdings Ltd. Shareholders 4Summary Letter to Hadasit Bio-Holdings Ltd. Shareholders 5Summary Letter to Hadasit Bio-Holdings Ltd. Shareholders 6SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System 2
(Date:9/30/2014)... New England Journal of Medicine reports positive ... drug crizotinib against the subset of lung cancer marked ... study of 50 patients with advanced non-small cell lung ... rate was 72 percent, with 3 complete responses and ... it takes for the disease to resume its growth ...
(Date:9/30/2014)... Munich report that a new class of chemical ... drugs. They have also pinpointed the relevant target ... agents. , Researchers led by LMU,s Professor ... Technische Universitt Mnchen have identified a class of ... the fight against malignant tumors. The compound is ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... Genetic factors explain some of the variation in a ... such as preferences toward environmental policy and financial ... variants are likely to be very small, according to ... Daniel Benjamin. The research team arrived at the ...
... by the European Commission,s in-house science service, the Joint Research ... managers on how to assess the environmental impacts of products ... resource-efficient Europe and aims to help design more sustainable products, ... and limited resources. , The increasing world population and ...
... created an ultrasensitive biosensor that could open up ... "personalized medicine" tailored to the specific biochemistry of ... several hundred times more sensitive than other biosensors, ... of sensors, said Muhammad A. Alam, a Purdue ...
Cached Biology News:New evidence that many genes of small effect influence economic decisions and political attitudes 2A practical guide to green products and services 2Ultrasensitive biosensor promising for medical diagnostics 2
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
Biology Products: